ScholarIQanswers from OpenAlex & ORCID
Vikram Deshpande
ResearcherPublications, citations & collaboration network
Vikram Deshpande is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does Vikram Deshpande have?
ScholarIQindexed works
Vikram Deshpande has 957 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Vikram Deshpande have?
ScholarIQcitation count
Vikram Deshpande has 59,008 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of Vikram Deshpande?
ScholarIQh-index
Vikram Deshpande has an h-index of 114 in OpenAlex.
What is the i10-index of Vikram Deshpande?
ScholarIQi10-index
Vikram Deshpande has an i10-index of 326 in OpenAlex.
What is the ORCID of Vikram Deshpande?
ScholarIQorcid
The ORCID for Vikram Deshpande is on the source record.
What is the OpenAlex record for Vikram Deshpande?
ScholarIQopenalex
The OpenAlex for Vikram Deshpande is on the source record.
What are the most-cited papers on Vikram Deshpande?
ScholarIQmost cited works
Consensus statement on the pathology of IgG4-related disease
Vikram Deshpande, Yoh Zen, John K. C. Chan, Eunhee E Yi, Yasuharu Sato, Tadashi Yoshino, Günter Klöppel, J.G. Heathcote, Arezou Khosroshahi, Judith A. Ferry, Rob C. Aalberse, Donald B. Bloch, William R. Brugge, Adrian C Bateman, Mollie N. Carruthers, Suresh T. Chari, Wah Cheuk, Lynn D. Cornell, Carlos Fernández‐del Castillo, David G. Forcione, Daniel L. Hamilos, Terumi Kamisawa, Satomi Kasashima, Shigeyuki Kawa, Mitsuhiro Kawano, Gregory Y. Lauwers, Yasufumi Masaki, Yasuni Nakanuma, Kenji Notohara, Kazuichi Okazaki, Ji Kon Ryu, Takako Saeki, Dushyant V. Sahani, Thomas C. Smyrk, James R. Stone, Masayuki Takahira, George Webster, Motohisa Yamamoto, Giuseppe Zamboni, Hisanori Umehara, John H. Stone
Recommendations for the nomenclature of IgG4‐related disease and its individual organ system manifestations
John H. Stone, Arezou Khosroshahi, Vikram Deshpande, John K. C. Chan, J.G. Heathcote, Rob C. Aalberse, Atsushi Azumi, Donald B. Bloch, William R. Brugge, Mollie N. Carruthers, Wah Cheuk, Lynn D. Cornell, Carlos Fernández‐del Castillo, Judith A. Ferry, David G. Forcione, Günter Klöppel, Daniel L. Hamilos, Terumi Kamisawa, Satomi Kasashima, Shigeyuki Kawa, Mitsuhiro Kawano, Yasufumi Masaki, Kenji Notohara, Kazuichi Okazaki, Ji Kon Ryu, Takako Saeki, Dushyant V. Sahani, Yasuharu Sato, Thomas C. Smyrk, James R. Stone, Masayuki Takahira, Hisanori Umehara, George Webster, Motohisa Yamamoto, Eunhee S. Yi, Tadashi Yoshino, Giuseppe Zamboni, Yoh Zen, Suresh T. Chari
Rituximab for IgG4-related disease: a prospective, open-label trial
Mollie N. Carruthers, Mark Topazian, Arezou Khosroshahi, Thomas E. Witzig, Zachary S. Wallace, Philip Hart, Vikram Deshpande, Thomas C. Smyrk, Suresh T. Chari, John H. Stone
IgG4‐Related Disease: Clinical and Laboratory Features in One Hundred Twenty‐Five Patients
Zachary S. Wallace, Vikram Deshpande, Hamid Mattoo, Vinay S. Mahajan, Maria Kulikova, Shiv Pillai, John H. Stone
Polyclonal Secondary <i>FGFR2</i> Mutations Drive Acquired Resistance to FGFR Inhibition in Patients with FGFR2 Fusion–Positive Cholangiocarcinoma
Lipika Goyal, Supriya K. Saha, Leah Y. Liu, Giulia Siravegna, Ignaty Leshchiner, Leanne G. Ahronian, Jochen K. Lennerz, Phuong Vu, Vikram Deshpande, Avinash Kambadakone, Benedetta Mussolin, Stephanie Reyes, Laura E. Henderson, Jiaoyuan Elisabeth Sun, Emily E. Van Seventer, Joseph M. Gurski, Sabrina Baltschukat, Barbara Schacher-Engstler, Louise Barys, Christelle Stamm, Pascal Furet, David P. Ryan, James R. Stone, A. John Iafrate, Gad Getz, Diana Graus Porta, Ralph Tiedt, Alberto Bardelli, Dejan Juric, Ryan B. Corcoran, Nabeel Bardeesy, Andrew X. Zhu